The DOI matches its OpenAlex record; 26 of the 26 references it cites were found in a registry or an index.
Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization
Abstract
PURPOSE: To define multimolecular phenotypes of adrenocortical carcinoma (ACC) and to correlate outcome with morphologic and molecular parameters. PATIENTS AND METHODS: Clinical data were analyzed for 124 patients, histopathologic slides for 67 primary tumors, and tissue specimens for 74 patients (38 primary and 36 metastatic tumors) with ACC and for 38 normal adrenal tissue samples. Molecular expression profiles were investigated by immunohistochemistry. The prognostic significance of 12 gross and histologic parameters in 67 primary ACCs was evaluated. Morphologic and protein expression patterns were correlated with disease-specific survival (DSS). Univariate influence of prognostic factors on DSS was analyzed by log-rank test and multivariate analysis by Cox regression. RESULTS: The median follow-up period was 4.7 years. Significant predictors of DSS included distant metastasis at time of initial presentation; venous, capsular, and adjacent organ invasion; tumor necrosis, mitotic rate, atypical mitosis, and mdm-2 overexpression. Five-year DSS by number (one to six) of adverse histologic parameters was as follows: one to two, 84%; three to four, 37%; more than four, 9% (P =.005). The phenotype Ki-67(-)p53(-)mdm-2(+)cyclinD1(-)Bcl-2(-)p21(-)p27(+) was observed in 83% of normal and 3% of malignant adrenal tissue (P =.01). Molecular phenotypic expression was more heterogeneous in malignant than in normal (10 v five phenotypes) adrenal tissue. CONCLUSION: Meticulous morphologic evaluation, mitotic count, and tumor stage are essential in determining prognosis for patients with ACC. Multimolecular phenotyping demonstrates that the molecular complexity and heterogeneity of these neoplasms are such that targeted therapy needs to be patient specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Prognostic significance of morphologic parameters in renal cell carcinoma
Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198210000-00007 · Cited by 2,724
BCL-2 FAMILY: Regulators of Cell Death
Chao, D. T., & Korsmeyer, S. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.395 · Cited by 1,685
Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors
Weiss, L. M. (1984) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198403000-00001 · Cited by 920
Gerdes, J., Li, L., Schlueter, C. J., Duchrow, M., Wohlenberg, C., Gerlach, C., Stahmer, I., Kloth, S., Brandt, E., & Flad, H. D. (1991) · PubMed · Cited by 889
Catzavelos, C., Bhattacharya, N., Ung, Y. C., Wilson, J. A., Roncari, L., Sandhu, C., Shaw, P., Yeger, H., Morava-Protzner, I., Kapusta, L., et al. (1997) · Nature Medicine · doi:10.1038/nm0297-227 · Cited by 823
Pathologic features of prognostic significance in adrenocortical carcinoma
Weiss, L. M., Medeiros, L. J., & Vickery, A. L. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198903000-00004 · Cited by 818
Luton, J.-P., Cerdas, S., Billaud, L., Thomas, G., Guilhaume, B., Bertagna, X., Laudat, M.-H., Louvel, A., Chapuis, Y., Blondeau, P., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004263221705 · Cited by 717
Tissue microarrays for gene amplification surveys in many different tumor types.
Schraml, P., Kononen, J., Bubendorf, L., Moch, H., Bissig, H., Nocito, A., Mihatsch, M. J., Kallioniemi, O., & Sauter, G. (1999) · PubMed · Cited by 433
Cited by
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
“The mitotic rate was found to be an independent predictor of disease-free survival in adrenocortical carcinoma and is, in combination with the presence of venous invasion, correlated best with metastasizing behavior (312, 315).”
BackgroundAdrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 764
Michalkiewicz, E., Sandrini, R., Figueiredo, B., Miranda, E. C. M., Caran, E., Oliveira-Filho, A. G., Marques, R., Pianovski, M. A. D., Lacerda, L., Cristofani, L. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.085 · Cited by 519
Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew, E., Reiff, E., Duh, Q., Clark, O. H., & McMillan, A. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0329-x · Cited by 451
Update in Adrenocortical Carcinoma
Fassnacht, M., Kroiss, M., & Allolio, B. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3020 · Cited by 414
Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling
Giordano, T. J., Kuick, R., Else, T., Gauger, P. G., Vinco, M., Bauersfeld, J., Sanders, D., Thomas, D. G., Doherty, G., & Hammer, G. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1067 · Cited by 401
Adrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
de Reyniès, A., Assié, G., Rickman, D. S., Tissier, F., Groussin, L., René-Corail, F., Dousset, B., Bertagna, X., Clauser, E., & Bertherat, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5678 · Cited by 382
Clinical management of adrenocortical carcinoma
Fassnacht, M., & Allolio, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.008 · Cited by 349
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center
Ayala-Ramirez, M., Jasim, S., Feng, L., Ejaz, S., Deniz, F., Busaidy, N., Waguespack, S. G., Naing, A., Sircar, K., Wood, C. G., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0519 · Cited by 293
Adrenocortical cancer: pathophysiology and clinical management
Libè, R., Fratticci, A., & Bertherat, J. (2007) · Endocrine-Related Cancer · doi:10.1677/erc.1.01130 · Cited by 272
Libé, R., Borget, I., Ronchi, C. L., Zaggia, B., Kroiss, M., Kerkhofs, T., Bertherat, J., Volante, M., Quinkler, M., Chabre, O., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv329 · Cited by 263
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma
Fassnacht, M., Hahner, S., Polat, B., Koschker, A.-C., Kenn, W., Flentje, M., & Allolio, B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1007 · Cited by 259
Prognostic parameters of metastatic adrenocortical carcinoma
Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236
Management of adrenocortical carcinoma
Allolio, B., Hahner, S., Weismann, D., & Fassnacht, M. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01881.x · Cited by 214
“Recently, Stojadinovic et al. (2002) have analysed additional parameters in a series of 124 patients using molecular expression profiles and morphologic patterns in tissue specimens.”
BackgroundRadiotherapy in adrenocortical carcinoma
Polat, B., Fassnacht, M., Pfreundner, L., Guckenberger, M., Bratengeier, K., Johanssen, S., Kenn, W., Hahner, S., Allolio, B., & Flentje, M. (2009) · Cancer · doi:10.1002/cncr.24331 · Cited by 189
The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors
Koch, C. A., Pacak, K., & Chrousos, G. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021069 · Cited by 177
Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma
Reibetanz, J., Jurowich, C., Erdogan, I., Nies, C., Rayes, N., Dralle, H., Behrend, M., Allolio, B., & Fassnacht, M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182367ac3 · Cited by 176
The role of surgery in the management of recurrent adrenocortical carcinoma
Erdogan, I., Deutschbein, T., Jurowich, C., Kroiss, M., Ronchi, C., Quinkler, M., Waldmann, J., Willenberg, H. S., Beuschlein, F., Fottner, C., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2559 · Cited by 154
“Recurrence rates of up to 85% have been reported (4, 5), although recent data suggest a relevant selection bias in most retrospective series (6).”
BackgroundGaujoux, S., Grabar, S., Fassnacht, M., Ragazzon, B., Launay, P., Libé, R., Chokri, I., Audebourg, A., Royer, B., Sbiera, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2006 · Cited by 146
Biology, clinical characteristics, and management of adrenocortical tumors in children
Rodriguez‐Galindo, C., Figueiredo, B. C., Zambetti, G. P., & Ribeiro, R. C. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20318 · Cited by 146
MORIMOTO, R., SATOH, F., MURAKAMI, O., SUZUKI, T., ABE, T., TANEMOTO, M., ABE, M., URUNO, A., ISHIDOYA, S., ARAI, Y., et al. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07-079 · Cited by 141
“onstrate high recurrence rate of up to 85% [1, 9], and histological and molecular markers for prediction of tumor behavior are therefore considered to be one of major concerns.”
BackgroundAdrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?
Leboulleux, S., Deandreis, D., Al Ghuzlan, A., Aupérin, A., Goéré, D., Dromain, C., Elias, D., Caillou, B., Travagli, J. P., De Baere, T., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-1096 · Cited by 133
Schmitt, A., Saremaslani, P., Schmid, S., Rousson, V, Montani, M., Schmid, D. M., Heitz, P. U., Komminoth, P., & Perren, A. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02505.x · Cited by 94
Urine steroid metabolomics as a novel tool for detection of recurrent adrenocortical carcinoma
Chortis, V., Bancos, I., Nijman, T., Gilligan, L. C., Taylor, A. E., Ronchi, C. L., O’Reilly, M. W., Schreiner, J., Asia, M., Riester, A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz141 · Cited by 93
“Disease recurrence rates are high, even in patients with microscopically complete (R0) resection (3,4).”
BackgroundProposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade
Miller, B. S., Gauger, P. G., Hammer, G. D., Giordano, T. J., & Doherty, G. M. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0698-y · Cited by 84
Sirianni, R., Zolea, F., Chimento, A., Ruggiero, C., Cerquetti, L., Fallo, F., Pilon, C., Arnaldi, G., Carpinelli, G., Stigliano, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2374 · Cited by 58
Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma
Dobrosotskaya, I. Y., Hammer, G. D., Schteingart, D. E., Maturen, K. E., & Worden, F. P. (2011) · Endocrine Practice · doi:10.4158/ep10390.cr · Cited by 53
Metadata
- Authors
- Stojadinovic, A., Ghossein, R. A., Hoos, A., Nissan, A., Marshall, D., Dudas, M. E., Cordon‐Cardo, C., Jaques, D. P., & Brennan, M. F.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-02-15
- Volume
- 20
- Issue
- 4
- Pages
- 941-950
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W2076710019
- Cited by
- 312
- References
- 26
- FWCI
- 9.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.